RxDoctor Payments Data

Patricia Rodriguez

Family · Austin, TXNPI 1801385281

Payments from drug & device makers

$5,525in general payments, 2019–2025

Across 202 payments — averaging $27.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Shockwave Medical, Inc$493
  • GSK$395
  • Boehringer Ingelheim$296
  • Bayer$219
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,525100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,525 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$32,464
Medicare patients
131
Services billed
1,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide24$32,251
TrulicityDulaglutide23$27,203
OzempicSemaglutide15$20,104
JardianceEmpagliflozin13$19,453
FarxigaDapagliflozin Propanediol14$14,237
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,726
Gabapentin34$906
Levothyroxine Sodium75$774
Pregabalin11$410
Trazodone Hcl32$402
Bupropion XlBupropion Hcl16$393
Rosuvastatin Calcium28$368
Quetiapine Fumarate12$367
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine16$366
Lisinopril38$351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$189$59,45447 claims
Novo NordiskOzempic$130$20,10415 claims
Boehringer IngelheimJardiance$296$19,45313 claims
AstraZenecaFarxiga$1,078$14,23714 claims
GSKTrelegy Ellipta$395$10,72611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →